{"entity":{"id":"nct07832630","kind":"trial","name":"Saruparib in HRDsig+ Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is not yet recruiting.","summary":"The registry lists NCT07832630 as not yet recruiting, last updated 2026-09-22. Enrolment is 124 planned participants, an estimate. Interventions: Saruparib, FoundationOne®CDx. Primary measures include Best objective response as determined by RECIST v.1.1. No results are posted in the registry; this does not exclude separate publications.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07832630","url":"https://clinicaltrials.gov/study/NCT07832630"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07832630","phase":"2","setting":"A Phase II Study of Saruparib in Patients With Platinum-Sensitive, HRDsig+ Solid Tumors","sponsor":"Abramson Cancer Center at Penn Medicine","started":"2026-11-01","startedType":"estimated","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07832630/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}